NCT06456359View on ClinicalTrials.gov

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Desmoplastic Small Round Cell TumorSynovial Sarcoma
Interventions
DRUG

Signifor

Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).

Trial Locations (4)

45147

NOT_YET_RECRUITING

Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie, Essen

69120

RECRUITING

National Center for Tumour Diseases, University Hospital Heidelberg, Heidelberg

70174

NOT_YET_RECRUITING

Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin, Stuttgart

70175

NOT_YET_RECRUITING

Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl, Stuttgart

All Listed Sponsors
lead

University Hospital Heidelberg

OTHER